Evidence brief - Health
The new claim reaches pancreatitis, not just a triglyceride number
The June 2026 label expansion is unusual because the trials captured an acute clinical event as well as a laboratory response.
- The indication begins at 500 mg/dLTryngolza is now approved with diet for adults with severe hypertriglyceridemia to reduce triglycerides and the risk of acute pancreatitis.
- The pooled event rate ratio was 0.15Across two placebo-controlled trials, independently adjudicated pancreatitis events were less frequent with pooled olezarsen over 53 weeks.
- The strongest signal came from the highest-risk subgroupTwenty-five of 29 adjudicated events occurred among participants with triglycerides of at least 880 mg/dL and a prior pancreatitis history.
The FDA expanded the U.S. indication for Tryngolza, or olezarsen, in June 2026. The monthly injection had already been approved for familial chylomicronemia syndrome. It can now be used with diet in adults with severe hypertriglyceridemia to reduce both triglycerides and the risk of acute pancreatitis.
That second verb matters. Lipid medicines are often discussed through laboratory values that stand in for later harm. Here the supporting program also counted attacks of acute pancreatitis, using a blinded independent committee and predefined diagnostic criteria. The evidence therefore moves beyond “the number fell,” while still requiring careful reading of who produced most of the events.
The label starts with severe hypertriglyceridemia
The indication is for adults whose fasting triglycerides are at least 500 mg/dL. It is an adjunct to diet, not permission to ignore alcohol exposure, diabetes control, medicines or other secondary causes that can push triglycerides upward.
A pancreatitis claim changes the evidence question
Very high concentrations of triglyceride-rich particles can overwhelm normal clearance. When chylomicrons accumulate, the risk of acute pancreatitis rises, particularly at the extreme end of the range and in people who have already had an attack. Pancreatitis can mean severe abdominal pain, hospitalization, organ complications and recurrence.
Before this expansion, medicines could be approved for lowering triglycerides without their pivotal trials accumulating enough pancreatitis events to establish a reduction in attacks. Olezarsen’s program was large enough, and enrolled enough high-risk participants, to support a clinical-event analysis. That is the real novelty of the approval.
Olezarsen removes a brake on particle clearance
Olezarsen is an antisense oligonucleotide directed at APOC3 messenger RNA in the liver. By reducing production of apolipoprotein C-III, it removes a signal that slows the breakdown and clearance of triglyceride-rich particles. The result is a lower circulating triglyceride burden.
Two trials created one event window
CORE-TIMI 72a and CORE2-TIMI 72b randomized 1,061 adults with severe hypertriglyceridemia to monthly olezarsen 50 mg, olezarsen 80 mg or placebo. The average baseline triglyceride concentration was 1,116 mg/dL. At month 6, both doses produced large placebo-adjusted reductions in both trials.
CORE-TIMI 72a
The 80 mg group recorded a 72% placebo-adjusted reduction. This trial contributed 617 participants to the pooled event analysis.
CORE2-TIMI 72b
The 80 mg group recorded a 55% placebo-adjusted reduction. This trial contributed 444 participants to the pooled event analysis.
Those lipid results were not perfectly identical across trials, and neither were the pancreatitis counts. In the first trial, 14 of 208 placebo participants had an adjudicated event versus two of 409 in the pooled olezarsen groups. In the second, three of 148 placebo participants and three of 296 olezarsen participants had an event. Pooling was prespecified and produced the estimate used in the label.
The Pancreatitis Attack Clock shows where the estimate comes from
A rate ratio compares event rates over observed time. It is not the same as saying that every person’s probability fell by 85%, and it does not mean the residual risk is zero. Recurrent attacks also matter because a participant can contribute more than one event.
Count attacks against time, then ask who carried the risk
The label combines both trials over Week 1 to Week 53. A blinded independent committee adjudicated events using the Revised Atlanta Diagnostic Criteria.
Five people had events; seven total adjudicated events occurred.
Seventeen people had events; 22 total adjudicated events occurred.
The subgroup combined baseline triglycerides of at least 880 mg/dL with a prior pancreatitis history.
The approved dose begins at 50 mg monthly
For adults with severe hypertriglyceridemia, the label recommends 50 mg by subcutaneous injection once each month. If that dose is tolerated and additional triglyceride reduction is clinically indicated, the dose may be increased to 80 mg. The label says the triglyceride-lowering effect may be measured within three months.
The dose distinction is not decorative. In the pooled analysis, both doses reduced event rates, but liver enzyme elevations were more frequent with 80 mg. Treatment is therefore not a contest to reach the largest possible laboratory change; it is a monitored decision about enough effect for a particular risk profile.
Injection-site reactions and liver enzyme increases
These were the adverse reactions occurring at least two percentage points more often than with placebo in adults with severe hypertriglyceridemia.
Liver tests belong to the dose decision
The label advises considering liver enzyme testing before initiation or dose escalation and thereafter when clinically indicated. Persistent elevations can justify interruption or dose reduction.
Lower pancreatitis risk does not make the condition disappear
Olezarsen is an adjunct to diet. Severe hypertriglyceridemia can reflect genetic susceptibility, uncontrolled diabetes, alcohol exposure, medications, obesity and other metabolic conditions. Those drivers still need attention because the treatment does not erase the system that produced the risk.
The label also warns about hypersensitivity reactions and increases in liver enzymes and hepatic fat. In a substudy, average hepatic fat fraction increased by two percentage points with 50 mg and four points with 80 mg at 12 months, versus no average increase with placebo; the clinical meaning remained uncertain. That uncertainty belongs beside the efficacy result, not hidden below it.
Questions about the new Tryngolza indication
Who is covered by the new indication?
Adults with severe hypertriglyceridemia, defined in the label as fasting triglycerides of at least 500 mg/dL. Tryngolza is used as an adjunct to diet.
Does a rate ratio of 0.15 mean risk falls to zero?
No. It compares adjudicated event rates between pooled olezarsen and placebo groups over the trial period. Absolute risk still depends on the patient and baseline risk.
Why does prior pancreatitis matter?
Most events occurred in the prespecified high-risk subgroup with triglycerides of at least 880 mg/dL and a history of pancreatitis. That concentration of events shaped the overall treatment effect.
Is this article individual medical advice?
No. It explains the public evidence and label. Treatment and monitoring decisions require a clinician who can evaluate causes, medicines, liver status and pancreatitis history.
Primary approval, label and trial sources
FDA evidence and trial records checked 18 August 2026
- FDA approval summary for the severe hypertriglyceridemia indication, 24 June 2026.
- Tryngolza U.S. Prescribing Information, revised June 2026.
- Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk, New England Journal of Medicine.
- CORE-TIMI 72a trial record, ClinicalTrials.gov.
- CORE2-TIMI 72b trial record, ClinicalTrials.gov.
This article explains population-level evidence and does not provide individual medical advice.
